J&J secures Actelion for US$30bn

Posted 27 January 2017

Johnson & Johnson has agreed to buy Actelion, Europe's biggest biotech company, for $US30 billion in a deal that will spin off the target's R&D arm.

The deal will help the US giant deal with the loss of exclusivity on Remicade (infliximab) by delivering a range of already successful treatments for conditions such as pulmonary arterial hypertension that are expected to boost sales by more than $US2 billion annually.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here